Immediate Impact
19 standout
Citing Papers
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection
2025 Standout
Works of Andrew Hill being referenced
Worldwide rates of diagnosis and effective treatment for cystic fibrosis
2022 Standout
Estimated costs of production and potential prices for the WHO Essential Medicines List
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Andrew Hill | 105 | 87 | 155 | 24 | 443 | |
| Steve Duff | 190 | 62 | 82 | 16 | 476 | |
| Heather Rozjabek | 81 | 42 | 89 | 23 | 496 | |
| Richard Tran | 83 | 146 | 47 | 20 | 380 | |
| Gowtham Rao | 107 | 97 | 30 | 24 | 434 | |
| Margaret Ryan | 98 | 86 | 40 | 27 | 437 | |
| R ROBERTS | 67 | 20 | 82 | 14 | 441 | |
| Luiz A.M. Fonseca | 131 | 26 | 47 | 24 | 402 | |
| Anderson Gonçalves | 151 | 62 | 76 | 29 | 459 | |
| Angela Ishak | 92 | 81 | 34 | 47 | 404 | |
| Houli Wang | 102 | 51 | 33 | 13 | 467 |
All Works
Login with ORCID to disown or claim papers
Loading papers...